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An estimated 10–20% of adults suffer from IBS, a func-
tional gastrointestinal disorder that negatively affects pa-
tient’s quality of life (QoL). As part of a one-year random-
ized, double blind, placebo-controlled study (S3B30006) of
the 5HT3 receptor antagonist alosetron in women with
IBS, QoL was assessed using the IBSQOL. OBJECTIVE:
To determine the smallest score change on each IBSQOL
scale that can be considered meaningful to the patient.
METHODS: The IBSQOL consists of nine scales, each
yielding a score of 0–100, with higher scores representing
better QoL. Subjects completed the IBSQOL at baseline
and both the IBSQOL and a global assessment question-
naire at months 1 and 2. The global assessment question-
naire contained nine items corresponding to the nine
scales of the IBSQOL. For each item, subjects rated the
change, if any, in a specific aspect of QoL relative to
baseline on a 7-point scale, ranging from “markedly
worse” to “markedly improved.” For each IBSQOL
scale, the average change score for subjects rating them-
selves as “slightly improved,” irrespective of treatment
group, was calculated to establish the minimum mean-
ingful difference (MMD). Average change scores for
“moderately improved” subjects were also calculated.
RESULTS: The MMDs were based on 90–127 subjects
per scale with the exception of sexual relations (n  46).
The following MMDs were determined: emotional—16.9
(SD  20.2); mental health—9.0 (18.7); sleep—11.6
(19.0); energy—18.6 (20.8); physical functioning—11.3
(19.0); food—12.5 (18.6); social functioning—14.5 (17.9);
role-physical—18.9 (19.1); sexual relations—19.4 (19.7).
Score changes corresponding to moderate improvements
were: emotional—24.8 (23.7); mental health—18.4
(18.6); sleep—18.4 (19.0); energy—30.4 (25.1); physical
functioning—20.8 (20.3); food—21.3 (19.4); social func-
tioning—27.2 (20.3); role-physical—27.4 (25.0); sexual
relations—26.1 (26.3). CONCLUSION: Determination
of MMDs for the IBSQOL may serve as a useful interpre-
tive tool.
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Evaluations of Integrated Therapeutics Group (ITG)
Asthma Health Management (AHM) programs have in-
cluded measures of clinical outcomes, utilization/medical
expenditures and QoL. To date, indirect costs have not
been systematically assessed. OBJECTIVES: As part of
an effort to develop and validate survey measures of pro-
ductivity, this study will present significant correlates of
baseline (pre-AHM implementation) mean annual costs
associated with missed days from work due to asthma.
METHODS: Data were obtained from self-reports from
a random sample of adult, employed asthmatics who
completed a mailed survey (N  1275) prior to participa-
tion in an AHM program. The dependent variable was
mean annual costs associated with missed days from
work due to asthma, derived by annualizing missed days
reported in the survey and multiplied by an estimate of
wages. Independent variables included sociodemograph-
ics, health status measures, asthma-related symptomatol-
ogy, utilization of medical services/pharmaceuticals, atti-
tudes and beliefs. RESULTS: Mean annual indirect costs
were $647 (95% CI $541–$754). In order of entrance
into a multiple regression equation, significant predictors
(P  0.05) of increased costs were: 1) asthma-related ER/
inpatient episode; 2) rating of health status as fair/poor;
3) low self-confidence in ability to manage asthma); 4)
adverse symptomatology profile; (5) comorbidity of res-
piratory allergies; and 6) daily use of bronchodilators. As
obtained from the multivariate model, an ER/inpatient
episode generated an increase of $998 associated with
missed work days, and relative to their more confident
counterparts, patients with less confidence had increased
expenditures of $344. CONCLUSIONS: Consistent with
national data, this study reveals a substantial indirect
cost burden associated with asthma. One year follow-up
data on the impact of the ITG AHM program on these
indirect costs will be presented.
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OBJECTIVE: This paper investigates the extent to which
absenteeism among newly diagnosed, employed patients
with depression varied among those who initiated treat-
ment with a TCA or SSRI. Subjects were drawn from the
MEDSTAT® Group’s MarketScan® and Illumina® Da-
tabases. METHODS: These databases include informa-
tion on the health care use of workers of large employers
in the US. The final analytical sample contained 716
newly diagnosed employees between 1994–1996 who
had absenteeism data available. Patterns of absenteeism
over the six-months prior to and twelve-months follow-
ing the initiation of pharmacotherapy were examined. In
addition, the number of absences during the twelve-
month follow-up period was analyzed using a multivari-
ate regression method specifically designed for non-nega-
tive dependent variables. RESULTS: Mean monthly ab-
sences equaled 4.7 at six-months prior to drug treatment
and rose to 10.2 during the month of initial antidepres-
sant treatment. Six-months after antidepressant treat-
ment commenced, absences declined approximately 40%
to 6 per month. The mean number of total absences dur-
